[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f2l0c-UJYjrw_6HE54uMHHvtq3rp_qf8affflhIVPvZ4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":54,"rows":61},"University of Florence",[4],74,false,15,3,14424,4,51,[14,17,20,23,25,27,29,31],{"name":15,"count":16},"Migraine",7,{"name":18,"count":19},"Chronic Migraine",6,{"name":21,"count":22},"Migraine With Aura",5,{"name":24,"count":22},"Migraine Without Aura",{"name":26,"count":11},"Cystic Fibrosis",{"name":28,"count":9},"Lower Urinary Tract Symptoms",{"name":30,"count":9},"Prostatic Hyperplasia",{"name":32,"count":9},"Bladder Cancer",[34,39,44,49],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05903027","Gepant treAtments: EffectIveNess and tolERability (GAINER)","2024-06-15","Rimegepant 75 MG Disintegrating Oral",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06414044","Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients","2025-11-30","Atogepant 60 mg",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06628921","The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)","2026-10-30","Eptinezumab 100 or 300 mg ev",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06409832","RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment","2027-01-01","Rimegepant 75 mg",[55,56,57,58,59,60],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[62,97,116,136,157,184,202,230,262,280,298,316,334,352,370,400,418,443,468,493,519,537,563,591,609,635,660,685,711,737,764,798,816,834,852],{"intervention":48,"totalTrials":63,"cells":64},2,{"EARLY_PHASE1":65,"PHASE1":68,"PHASE2":70,"PHASE3":72,"PHASE4":74,"NA":76},{"trials":66,"activeCount":67},[],0,{"trials":69,"activeCount":67},[],{"trials":71,"activeCount":67},[],{"trials":73,"activeCount":67},[],{"trials":75,"activeCount":67},[],{"trials":77,"activeCount":96,"soonestReadout":47},[78,89],{"nctId":79,"briefTitle":80,"status":81,"phases":82,"primaryCompletion":83,"completion":84,"start":85,"enrollment":86,"conditions":87,"interventions":88},"NCT06409845","Effectiveness and Tolerability of Eptinezumab","UNKNOWN",[],"2025-04","2026-04","2024-03-26",100,[15,21,24,18],[48],{"nctId":45,"briefTitle":46,"status":90,"phases":91,"primaryCompletion":47,"completion":47,"start":92,"enrollment":93,"conditions":94,"interventions":95},"RECRUITING",[],"2024-10-30",50,[15],[48],1,{"intervention":53,"totalTrials":96,"cells":98},{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":109},{"trials":100,"activeCount":67},[],{"trials":102,"activeCount":67},[],{"trials":104,"activeCount":67},[],{"trials":106,"activeCount":67},[],{"trials":108,"activeCount":67},[],{"trials":110,"activeCount":96,"soonestReadout":52},[111],{"nctId":50,"briefTitle":51,"status":90,"phases":112,"primaryCompletion":52,"completion":113,"start":85,"enrollment":86,"conditions":114,"interventions":115},[],"2027-09",[15,21,24,18],[53],{"intervention":38,"totalTrials":96,"cells":117},{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":128},{"trials":119,"activeCount":67},[],{"trials":121,"activeCount":67},[],{"trials":123,"activeCount":67},[],{"trials":125,"activeCount":67},[],{"trials":127,"activeCount":67},[],{"trials":129,"activeCount":96,"soonestReadout":37},[130],{"nctId":35,"briefTitle":36,"status":90,"phases":131,"primaryCompletion":37,"completion":132,"start":133,"enrollment":86,"conditions":134,"interventions":135},[],"2026-09-15","2023-06-15",[15,21,24,18],[38],{"intervention":43,"totalTrials":96,"cells":137},{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":148},{"trials":139,"activeCount":67},[],{"trials":141,"activeCount":67},[],{"trials":143,"activeCount":67},[],{"trials":145,"activeCount":67},[],{"trials":147,"activeCount":67},[],{"trials":149,"activeCount":96,"soonestReadout":42},[150],{"nctId":40,"briefTitle":41,"status":151,"phases":152,"primaryCompletion":42,"completion":84,"start":153,"enrollment":154,"conditions":155,"interventions":156},"ACTIVE_NOT_RECRUITING",[],"2024-05-09",500,[15,21,24,18],[43],{"intervention":158,"totalTrials":96,"cells":159},"G-CSF",{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":182},{"trials":161,"activeCount":67},[],{"trials":163,"activeCount":67},[],{"trials":165,"activeCount":67},[],{"trials":167,"activeCount":67},[],{"trials":169,"activeCount":67},[170],{"nctId":171,"briefTitle":172,"status":173,"phases":174,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":180},"NCT00772122","Use of G-CSF for the Treatment of Unexplained Recurrent Miscarriage","COMPLETED",[59],"2007-01","2000-01",68,[179],"Habitual Abortion",[158,181],"saline solution",{"trials":183,"activeCount":67},[],{"intervention":181,"totalTrials":96,"cells":185},{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":192,"PHASE4":194,"NA":200},{"trials":187,"activeCount":67},[],{"trials":189,"activeCount":67},[],{"trials":191,"activeCount":67},[],{"trials":193,"activeCount":67},[],{"trials":195,"activeCount":67},[196],{"nctId":171,"briefTitle":172,"status":173,"phases":197,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":198,"interventions":199},[59],[179],[158,181],{"trials":201,"activeCount":67},[],{"intervention":203,"totalTrials":96,"cells":204},"Combined Estrogen-Progestin Oral Contraceptives",{"EARLY_PHASE1":205,"PHASE1":207,"PHASE2":209,"PHASE3":211,"PHASE4":213,"NA":228},{"trials":206,"activeCount":67},[],{"trials":208,"activeCount":67},[],{"trials":210,"activeCount":67},[],{"trials":212,"activeCount":67},[],{"trials":214,"activeCount":67},[215],{"nctId":216,"briefTitle":217,"status":173,"phases":218,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":227},"NCT02613039","Oral Contraceptive Therapy and Sexuality",[59],"2018-02","2019-02","2015-10",10,[224,225,226],"Contraceptive Usage","Sexual Behavior","Mental Health Wellness 1",[203],{"trials":229,"activeCount":67},[],{"intervention":231,"totalTrials":96,"cells":232},"Sugammadex",{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":260},{"trials":234,"activeCount":67},[],{"trials":236,"activeCount":67},[],{"trials":238,"activeCount":67},[],{"trials":240,"activeCount":67},[],{"trials":242,"activeCount":67},[243],{"nctId":244,"briefTitle":245,"status":81,"phases":246,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":253},"NCT02698969","Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography",[59],"2017-02","2017-07","2014-11",58,[252],"Post-operative Residual Curarization",[231,254,255,256,257,258,259],"Neostigmine","Atropine","Rocuronium","Fentanyl","Propofol","Sevoflurane",{"trials":261,"activeCount":67},[],{"intervention":254,"totalTrials":96,"cells":263},{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":270,"PHASE4":272,"NA":278},{"trials":265,"activeCount":67},[],{"trials":267,"activeCount":67},[],{"trials":269,"activeCount":67},[],{"trials":271,"activeCount":67},[],{"trials":273,"activeCount":67},[274],{"nctId":244,"briefTitle":245,"status":81,"phases":275,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":276,"interventions":277},[59],[252],[231,254,255,256,257,258,259],{"trials":279,"activeCount":67},[],{"intervention":255,"totalTrials":96,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":290,"NA":296},{"trials":283,"activeCount":67},[],{"trials":285,"activeCount":67},[],{"trials":287,"activeCount":67},[],{"trials":289,"activeCount":67},[],{"trials":291,"activeCount":67},[292],{"nctId":244,"briefTitle":245,"status":81,"phases":293,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":294,"interventions":295},[59],[252],[231,254,255,256,257,258,259],{"trials":297,"activeCount":67},[],{"intervention":256,"totalTrials":96,"cells":299},{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":306,"PHASE4":308,"NA":314},{"trials":301,"activeCount":67},[],{"trials":303,"activeCount":67},[],{"trials":305,"activeCount":67},[],{"trials":307,"activeCount":67},[],{"trials":309,"activeCount":67},[310],{"nctId":244,"briefTitle":245,"status":81,"phases":311,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":312,"interventions":313},[59],[252],[231,254,255,256,257,258,259],{"trials":315,"activeCount":67},[],{"intervention":257,"totalTrials":96,"cells":317},{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":324,"PHASE4":326,"NA":332},{"trials":319,"activeCount":67},[],{"trials":321,"activeCount":67},[],{"trials":323,"activeCount":67},[],{"trials":325,"activeCount":67},[],{"trials":327,"activeCount":67},[328],{"nctId":244,"briefTitle":245,"status":81,"phases":329,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":330,"interventions":331},[59],[252],[231,254,255,256,257,258,259],{"trials":333,"activeCount":67},[],{"intervention":258,"totalTrials":96,"cells":335},{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":342,"PHASE4":344,"NA":350},{"trials":337,"activeCount":67},[],{"trials":339,"activeCount":67},[],{"trials":341,"activeCount":67},[],{"trials":343,"activeCount":67},[],{"trials":345,"activeCount":67},[346],{"nctId":244,"briefTitle":245,"status":81,"phases":347,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":348,"interventions":349},[59],[252],[231,254,255,256,257,258,259],{"trials":351,"activeCount":67},[],{"intervention":259,"totalTrials":96,"cells":353},{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":360,"PHASE4":362,"NA":368},{"trials":355,"activeCount":67},[],{"trials":357,"activeCount":67},[],{"trials":359,"activeCount":67},[],{"trials":361,"activeCount":67},[],{"trials":363,"activeCount":67},[364],{"nctId":244,"briefTitle":245,"status":81,"phases":365,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":366,"interventions":367},[59],[252],[231,254,255,256,257,258,259],{"trials":369,"activeCount":67},[],{"intervention":371,"totalTrials":96,"cells":372},"0,9% NaCl flush",{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":379,"PHASE4":381,"NA":398},{"trials":374,"activeCount":67},[],{"trials":376,"activeCount":67},[],{"trials":378,"activeCount":67},[],{"trials":380,"activeCount":67},[],{"trials":382,"activeCount":67},[383],{"nctId":384,"briefTitle":385,"status":386,"phases":387,"primaryCompletion":388,"completion":389,"start":390,"enrollment":391,"conditions":392,"interventions":396},"NCT01794767","Normal Saline Versus Heparinized Solution Flush for Maintaining Patency of Peripheral Venous Catheters in Children","SUSPENDED",[59],"2014-08","2016-08","2013-01",52,[393,394,395],"Infection of Intravenous Catheter","Phlebitis","Extravasation of Diagnostic and Therapeutic Materials",[371,397],"Heparin 50U\u002Fml",{"trials":399,"activeCount":67},[],{"intervention":397,"totalTrials":96,"cells":401},{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":408,"PHASE4":410,"NA":416},{"trials":403,"activeCount":67},[],{"trials":405,"activeCount":67},[],{"trials":407,"activeCount":67},[],{"trials":409,"activeCount":67},[],{"trials":411,"activeCount":67},[412],{"nctId":384,"briefTitle":385,"status":386,"phases":413,"primaryCompletion":388,"completion":389,"start":390,"enrollment":391,"conditions":414,"interventions":415},[59],[393,394,395],[371,397],{"trials":417,"activeCount":67},[],{"intervention":419,"totalTrials":96,"cells":420},"Testosterone gel 2%",{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":429,"NA":441},{"trials":422,"activeCount":67},[],{"trials":424,"activeCount":67},[],{"trials":426,"activeCount":67},[],{"trials":428,"activeCount":67},[],{"trials":430,"activeCount":67},[431],{"nctId":432,"briefTitle":433,"status":173,"phases":434,"primaryCompletion":435,"completion":247,"start":436,"enrollment":437,"conditions":438,"interventions":440},"NCT02366975","TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST",[59],"2017-01","2012-11",143,[30,28,439],"Hypogonadism",[419],{"trials":442,"activeCount":67},[],{"intervention":444,"totalTrials":96,"cells":445},"Tadalafil",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":454,"NA":466},{"trials":447,"activeCount":67},[],{"trials":449,"activeCount":67},[],{"trials":451,"activeCount":67},[],{"trials":453,"activeCount":67},[],{"trials":455,"activeCount":67},[456],{"nctId":457,"briefTitle":458,"status":173,"phases":459,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":465},"NCT02252367","Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms",[59],"2019-01","2020-06","2015-12",86,[30,28],[444],{"trials":467,"activeCount":67},[],{"intervention":469,"totalTrials":96,"cells":470},"Vardenafil",{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":477,"PHASE4":479,"NA":491},{"trials":472,"activeCount":67},[],{"trials":474,"activeCount":67},[],{"trials":476,"activeCount":67},[],{"trials":478,"activeCount":67},[],{"trials":480,"activeCount":67},[481],{"nctId":482,"briefTitle":483,"status":173,"phases":484,"primaryCompletion":485,"completion":485,"start":486,"enrollment":487,"conditions":488,"interventions":490},"NCT02450188","Vardenafil and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV)",[59],"2014-01","2012-03",30,[489],"Erectile Dysfunction",[469],{"trials":492,"activeCount":67},[],{"intervention":494,"totalTrials":96,"cells":495},"Transplantation of circulating CD14+CD34+cells",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":515,"NA":517},{"trials":497,"activeCount":67},[],{"trials":499,"activeCount":67},[],{"trials":501,"activeCount":67},[],{"trials":503,"activeCount":67},[504],{"nctId":505,"briefTitle":506,"status":173,"phases":507,"primaryCompletion":508,"completion":221,"start":509,"enrollment":510,"conditions":511,"interventions":513},"NCT02454231","Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA)",[57,58],"2015-05","2009-09",45,[512],"Critical Limb Ischemia",[494,514],"Transplantation of BM MNC",{"trials":516,"activeCount":67},[],{"trials":518,"activeCount":67},[],{"intervention":514,"totalTrials":96,"cells":520},{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":533,"NA":535},{"trials":522,"activeCount":67},[],{"trials":524,"activeCount":67},[],{"trials":526,"activeCount":67},[],{"trials":528,"activeCount":67},[529],{"nctId":505,"briefTitle":506,"status":173,"phases":530,"primaryCompletion":508,"completion":221,"start":509,"enrollment":510,"conditions":531,"interventions":532},[57,58],[512],[494,514],{"trials":534,"activeCount":67},[],{"trials":536,"activeCount":67},[],{"intervention":538,"totalTrials":96,"cells":539},"Ibuprofen",{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":546,"PHASE4":559,"NA":561},{"trials":541,"activeCount":67},[],{"trials":543,"activeCount":67},[],{"trials":545,"activeCount":67},[],{"trials":547,"activeCount":67},[548],{"nctId":549,"briefTitle":550,"status":173,"phases":551,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":556,"interventions":558},"NCT01243996","High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant",[57,58],"2010-05","2010-10","2008-06",70,[557],"Ductus Arteriosus, Patent",[538],{"trials":560,"activeCount":67},[],{"trials":562,"activeCount":67},[],{"intervention":564,"totalTrials":96,"cells":565},"comparison of different dosage of clopidogrel",{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":572,"PHASE4":587,"NA":589},{"trials":567,"activeCount":67},[],{"trials":569,"activeCount":67},[],{"trials":571,"activeCount":67},[],{"trials":573,"activeCount":67},[574],{"nctId":575,"briefTitle":576,"status":81,"phases":577,"primaryCompletion":578,"completion":579,"start":580,"enrollment":581,"conditions":582,"interventions":585},"NCT00774475","Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition",[58],"2010-11","2011-01","2008-11",442,[583,584],"Unstable Angina","NSTEMI",[564,586],"doubled therapy",{"trials":588,"activeCount":67},[],{"trials":590,"activeCount":67},[],{"intervention":586,"totalTrials":96,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":605,"NA":607},{"trials":594,"activeCount":67},[],{"trials":596,"activeCount":67},[],{"trials":598,"activeCount":67},[],{"trials":600,"activeCount":67},[601],{"nctId":575,"briefTitle":576,"status":81,"phases":602,"primaryCompletion":578,"completion":579,"start":580,"enrollment":581,"conditions":603,"interventions":604},[58],[583,584],[564,586],{"trials":606,"activeCount":67},[],{"trials":608,"activeCount":67},[],{"intervention":610,"totalTrials":96,"cells":611},"CC-486",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":629,"PHASE4":631,"NA":633},{"trials":613,"activeCount":67},[],{"trials":615,"activeCount":67},[],{"trials":617,"activeCount":67},[618],{"nctId":619,"briefTitle":620,"status":173,"phases":621,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":628},"NCT04806906","Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients",[57],"2025-01-24","2021-03-24",11,[626,627],"MDS","CMML",[610],{"trials":630,"activeCount":67},[],{"trials":632,"activeCount":67},[],{"trials":634,"activeCount":67},[],{"intervention":636,"totalTrials":96,"cells":637},"Elbasvir\u002FGrazoprevir",{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":646,"NA":648},{"trials":639,"activeCount":67},[],{"trials":641,"activeCount":67},[],{"trials":643,"activeCount":67},[],{"trials":645,"activeCount":67},[],{"trials":647,"activeCount":67},[],{"trials":649,"activeCount":67},[650],{"nctId":651,"briefTitle":652,"status":81,"phases":653,"primaryCompletion":654,"completion":654,"start":655,"enrollment":510,"conditions":656,"interventions":659},"NCT03433326","Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy",[],"2018-12-31","2018-03-01",[657,658],"Hepatitis C","Cryoglobulinaemic Glomerulonephritis",[636],{"intervention":661,"totalTrials":96,"cells":662},"Dalteparin",{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":671,"NA":673},{"trials":664,"activeCount":67},[],{"trials":666,"activeCount":67},[],{"trials":668,"activeCount":67},[],{"trials":670,"activeCount":67},[],{"trials":672,"activeCount":67},[],{"trials":674,"activeCount":67},[675],{"nctId":676,"briefTitle":677,"status":678,"phases":679,"completion":680,"start":681,"conditions":682,"interventions":684},"NCT00260520","LMWH to Prevent Preeclampsia and Fetal Growth Restriction","TERMINATED",[],"2003-12","2002-01",[683],"Preeclampsia",[661],{"intervention":686,"totalTrials":96,"cells":687},"Caffeine Citrate",{"EARLY_PHASE1":688,"PHASE1":690,"PHASE2":692,"PHASE3":694,"PHASE4":696,"NA":698},{"trials":689,"activeCount":67},[],{"trials":691,"activeCount":67},[],{"trials":693,"activeCount":67},[],{"trials":695,"activeCount":67},[],{"trials":697,"activeCount":67},[],{"trials":699,"activeCount":67},[700],{"nctId":701,"briefTitle":702,"status":173,"phases":703,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":708,"interventions":710},"NCT04044976","Caffeine Treatment in in the Delivery Room",[60],"2021-06-30","2021-08-31","2019-08-01",42,[709],"Respiratory Distress Syndrome",[686],{"intervention":712,"totalTrials":96,"cells":713},"Tadalafil 5mg",{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":720,"PHASE4":722,"NA":724},{"trials":715,"activeCount":67},[],{"trials":717,"activeCount":67},[],{"trials":719,"activeCount":67},[],{"trials":721,"activeCount":67},[],{"trials":723,"activeCount":67},[],{"trials":725,"activeCount":67},[726],{"nctId":727,"briefTitle":728,"status":173,"phases":729,"primaryCompletion":730,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":736},"NCT04383093","Tadalafil Plus Tamsulosin for Male LUTS and ED",[],"2018-01-01","2017-01-01",75,[734,28,489,735],"Prostatic Hyperplasia, Benign","Metabolic Syndrome",[712],{"intervention":738,"totalTrials":96,"cells":739},"Chemotherapy",{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":741,"activeCount":67},[],{"trials":743,"activeCount":67},[],{"trials":745,"activeCount":67},[],{"trials":747,"activeCount":67},[],{"trials":749,"activeCount":67},[],{"trials":751,"activeCount":67},[752],{"nctId":753,"briefTitle":754,"status":81,"phases":755,"primaryCompletion":756,"completion":757,"start":758,"enrollment":86,"conditions":759,"interventions":763},"NCT04495387","Improving Food Pleasure and Intake of Oncology Patients Receiving Chemotherapy",[],"2022-01","2022-12","2021-07",[760,761,762],"Colon Cancer","Breast Cancer","Chemotherapeutic Toxicity",[738],{"intervention":765,"totalTrials":96,"cells":766},"Testosterone gel",{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":773,"PHASE4":775,"NA":777},{"trials":768,"activeCount":67},[],{"trials":770,"activeCount":67},[],{"trials":772,"activeCount":67},[],{"trials":774,"activeCount":67},[],{"trials":776,"activeCount":67},[],{"trials":778,"activeCount":67},[779],{"nctId":780,"briefTitle":781,"status":173,"phases":782,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":794},"NCT04336891","Effect of Testosterone Treatment on Clitoral Arteries' Hemodynamic Parameters.",[],"2019-12-31","2020-03-31","2019-03-20",81,[788,789,790,791,792,793],"Hypoactive Sexual Desire Disorder","Vulvovaginal Disease","Menopause Related Conditions","Dyspareunia (Female Excluding Psychogenic)","Hypoestrogenism","Arousal Disorders, Sexual",[765,795,796,797],"Estradiol ovules","Moisturizer","Testosterone gel + Estradiol ovules",{"intervention":795,"totalTrials":96,"cells":799},{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":808,"NA":810},{"trials":801,"activeCount":67},[],{"trials":803,"activeCount":67},[],{"trials":805,"activeCount":67},[],{"trials":807,"activeCount":67},[],{"trials":809,"activeCount":67},[],{"trials":811,"activeCount":67},[812],{"nctId":780,"briefTitle":781,"status":173,"phases":813,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":814,"interventions":815},[],[788,789,790,791,792,793],[765,795,796,797],{"intervention":796,"totalTrials":96,"cells":817},{"EARLY_PHASE1":818,"PHASE1":820,"PHASE2":822,"PHASE3":824,"PHASE4":826,"NA":828},{"trials":819,"activeCount":67},[],{"trials":821,"activeCount":67},[],{"trials":823,"activeCount":67},[],{"trials":825,"activeCount":67},[],{"trials":827,"activeCount":67},[],{"trials":829,"activeCount":67},[830],{"nctId":780,"briefTitle":781,"status":173,"phases":831,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":832,"interventions":833},[],[788,789,790,791,792,793],[765,795,796,797],{"intervention":797,"totalTrials":96,"cells":835},{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":842,"PHASE4":844,"NA":846},{"trials":837,"activeCount":67},[],{"trials":839,"activeCount":67},[],{"trials":841,"activeCount":67},[],{"trials":843,"activeCount":67},[],{"trials":845,"activeCount":67},[],{"trials":847,"activeCount":67},[848],{"nctId":780,"briefTitle":781,"status":173,"phases":849,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":850,"interventions":851},[],[788,789,790,791,792,793],[765,795,796,797],{"intervention":853,"totalTrials":96,"cells":854},"Lasmiditan",{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":861,"PHASE4":863,"NA":865},{"trials":856,"activeCount":67},[],{"trials":858,"activeCount":67},[],{"trials":860,"activeCount":67},[],{"trials":862,"activeCount":67},[],{"trials":864,"activeCount":67},[],{"trials":866,"activeCount":67},[867],{"nctId":868,"briefTitle":869,"status":173,"phases":870,"primaryCompletion":871,"completion":872,"start":133,"enrollment":86,"conditions":873,"interventions":874},"NCT05903040","Ditan Acute tReatments: Effectiveness and Tolerability (DART)",[],"2024-06-01","2025-12-01",[15,21,24,18],[853]]